Two Bennett VHH design targets have no outcome row
Targets without printed outcome of Fine-tuned RFdiffusion antibody design pipeline (RFantibody)
Supplementary Methods Table 5 rows: HIV Env (2NY7), SARS-CoV-2 RBD (6M0J), RSV-F Site I (7LVW), RSV-F Site III (7LUC), Influenza Hemagglutinin (5VLI), TcdB (6C0B), IL-7 Receptor alpha (3DI3). Section 6.8 states 'We designed VHHs against 6 targets in total', which does not match the seven rows. Table 6's caption states 'For 5 targets for which de novo VHH binders were identified, details are provided', and Table 6 has rows only for TcdB, IL7R, H1 stem (twice), SARS-CoV-2 RBD and RSV site 3. No outcome is printed for RSV-F site I or HIV Env, and none is inferred here.
Supplementary Methods Table 5 lists seven design targets and Table 6 reports five, because its caption restricts it to the targets for which binders were identified. RSV-F site I and HIV Env therefore have no printed outcome, and their absence is not a recorded zero.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
12 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Claimed field targets_without_printed_outcome Context-only references | Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 | not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Claimed field targets_without_printed_outcome Context-only references | Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 |
| Source location Supplementary Methods Tables 5 and 6; Section 6.8 Context-only references | Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 | not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Source location Supplementary Methods Tables 5 and 6; Section 6.8 Context-only references | Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 |
| Claimed value Supplementary Methods Table 5 rows: HIV Env (2NY7), SARS-CoV-2 RBD (6M0J), RSV-F Site I (7LVW), RSV-F Site III (7LUC), Influenza Hemagglutinin (5VLI), TcdB (6C0B), IL-7 Receptor alpha (3DI3). Section 6.8 states 'We designed VHHs against 6 targets in total', which does not match the seven rows. Table 6's caption states 'For 5 targets for which de novo VHH binders were identified, details are provided', and Table 6 has rows only for TcdB, IL7R, H1 stem (twice), SARS-CoV-2 RBD and RSV site 3. No outcome is printed for RSV-F site I or HIV Env, and none is inferred here. Context-only references | Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 | not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Claimed value Supplementary Methods Table 5 rows: HIV Env (2NY7), SARS-CoV-2 RBD (6M0J), RSV-F Site I (7LVW), RSV-F Site III (7LUC), Influenza Hemagglutinin (5VLI), TcdB (6C0B), IL-7 Receptor alpha (3DI3). Section 6.8 states 'We designed VHHs against 6 targets in total', which does not match the seven rows. Table 6's caption states 'For 5 targets for which de novo VHH binders were identified, details are provided', and Table 6 has rows only for TcdB, IL7R, H1 stem (twice), SARS-CoV-2 RBD and RSV site 3. No outcome is printed for RSV-F site I or HIV Env, and none is inferred here. Context-only references | Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 |
| Description Supplementary Methods Table 5 lists seven design targets and Table 6 reports five, because its caption restricts it to the targets for which binders were identified. RSV-F site I and HIV Env therefore have no printed outcome, and their absence is not a recorded zero. Context-only references | Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 | not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Description Supplementary Methods Table 5 lists seven design targets and Table 6 reports five, because its caption restricts it to the targets for which binders were identified. RSV-F site I and HIV Env therefore have no printed outcome, and their absence is not a recorded zero. Context-only references | Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 |
| Relationship: subject uc-binder-20261022-pipeline-bennett-rfdiffusion-antibody Context-only references | Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 | not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Relationship: subject uc-binder-20261022-pipeline-bennett-rfdiffusion-antibody Context-only references | Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Supplementary Methods Tables 5 and 6; Section 6.8 Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 |
Sources and history
Release 2026-10-22-1b7cf027e4f6 · Record review: source checked
2 source records and release history
- Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 · Original source · Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15
- Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Original source · Nature, version of record; Europe PMC JATS full text for PMC12727541
Technical metadata and extraction receipts
Stable ID: uc-binder-20261022-claim-bennett-targets-without-table6-row
- field
- targets_without_printed_outcome
- review
- artifact sha256: f5d4fc4f3a65a2dc3ab696e165bb86bf150b2437cdc1a7046cfbecae8ccab05c; method: source-hash-verification; independent-cell-check; ai-assisted-source-review; method note: The supplementary archive now returns 107,210,814 bytes and extracts cleanly with unzip, where the extraction pass received a truncated 103,690,987-byte archive it had to stream with bsdtar. The pinned member hash is what matters and it matched exactly: 41586_2025_9721_MOESM1_ESM.pdf is f5d4fc4f3a65a2dc3ab696e165bb86bf150b2437cdc1a7046cfbecae8ccab05c. Own text layer with pdftotext -layout (poppler 26.08.0), reproducing 3,582 lines; Supplementary Methods Tables 5 and 6 read cell by cell.; note: Reviewed in docs/reviews/use-cases/binder-2026-10-22.md. Automated AI review of the source transcription only; it is not human scientific review and nothing here was reproduced experimentally.; retrieval url: https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12727541/supplementaryFiles; reviewed at: 2026-10-22T15:00:00Z; reviewer: claude; reviewer note: Claude review agent, independent of the extraction agent; no human review claimed
- source locator
- Supplementary Methods Tables 5 and 6; Section 6.8
- value
- Supplementary Methods Table 5 rows: HIV Env (2NY7), SARS-CoV-2 RBD (6M0J), RSV-F Site I (7LVW), RSV-F Site III (7LUC), Influenza Hemagglutinin (5VLI), TcdB (6C0B), IL-7 Receptor alpha (3DI3). Section 6.8 states 'We designed VHHs against 6 targets in total', which does not match the seven rows. Table 6's caption states 'For 5 targets for which de novo VHH binders were identified, details are provided', and Table 6 has rows only for TcdB, IL7R, H1 stem (twice), SARS-CoV-2 RBD and RSV site 3. No outcome is printed for RSV-F site I or HIV Env, and none is inferred here.